Staar Surgical CO STAA
We take great care to ensure that the data presented and summarized in this overview for STAAR SURGICAL CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding STAA
View all-
Broadwood Capital Inc New York, NY10.8MShares$313 Million31.02% of portfolio
-
Black Rock Inc. New York, NY7.49MShares$218 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.54MShares$161 Million0.0% of portfolio
-
State Street Corp Boston, MA1.94MShares$56.5 Million0.0% of portfolio
-
Baillie Gifford & CO1.46MShares$42.5 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA1.17MShares$34.2 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA1.09MShares$31.8 Million5.58% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il934KShares$27.2 Million0.01% of portfolio
-
Morgan Stanley New York, NY844KShares$24.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny842KShares$24.5 Million0.02% of portfolio
Latest Institutional Activity in STAA
Top Purchases
Top Sells
About STAA
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Insider Transactions at STAA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 12
2024
|
Arthur C Butcher |
BUY
Open market or private purchase
|
Direct |
1,315
+23.81%
|
$48,655
$37.99 P/Share
|
Jun 20
2024
|
Aimee S Weisner |
BUY
Grant, award, or other acquisition
|
Direct |
4,488
+22.62%
|
-
|
Jun 20
2024
|
Lilian Yansheng Zhou |
BUY
Grant, award, or other acquisition
|
Direct |
2,244
+32.93%
|
-
|
Jun 20
2024
|
Stephen C Farrell |
BUY
Grant, award, or other acquisition
|
Direct |
2,244
+12.9%
|
-
|
Jun 20
2024
|
Elizabeth Yeu Lin |
BUY
Grant, award, or other acquisition
|
Direct |
2,244
+30.56%
|
-
|
Jun 20
2024
|
Wei Jiang |
BUY
Grant, award, or other acquisition
|
Direct |
2,244
+38.78%
|
-
|
Jun 20
2024
|
Arthur C Butcher |
BUY
Grant, award, or other acquisition
|
Direct |
2,244
+43.68%
|
-
|
May 09
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
May 09
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1
|
$42
$42.56 P/Share
|
May 08
2024
|
Magda Michna Chief Clinical, Regulatory, |
SELL
Payment of exercise price or tax liability
|
Direct |
1,670
-11.89%
|
$68,470
$41.02 P/Share
|
May 08
2024
|
Warren Foust Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,418
-11.89%
|
$99,138
$41.02 P/Share
|
Mar 14
2024
|
Aimee S Weisner |
BUY
Open market or private purchase
|
Direct |
1,750
+13.87%
|
$66,500
$38.11 P/Share
|
Mar 12
2024
|
Wei Jiang |
BUY
Grant, award, or other acquisition
|
Direct |
1,299
+50.0%
|
-
|
Mar 12
2024
|
Arthur C Butcher |
BUY
Grant, award, or other acquisition
|
Direct |
649
+50.0%
|
-
|
Mar 07
2024
|
Patrick F. Williams Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,614
+5.44%
|
-
|
Jan 08
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Jan 08
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
4,042
+0.04%
|
$109,134
$27.11 P/Share
|
Jan 05
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Jan 05
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
156,734
+0.72%
|
$4,388,552
$28.68 P/Share
|
Jan 04
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 45.2K shares |
---|---|
Open market or private purchase | 235K shares |
Exercise of conversion of derivative security | 2.61K shares |
Payment of exercise price or tax liability | 14.8K shares |
---|